

cancer, lymph node cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.

5/29. A process for the preparation of a pharmaceutical composition of claim 1, which comprises processing components 1, 2, and 3 into a pharmaceutically acceptable form for administration.--

IN THE ABSTRACT:

Please delete the Abstract and insert therefor the Abstract set forth on the attached sheet.

REMARKS

Claims 1-11 have been cancelled and replaced by claims 12-29 to comport with U.S. practice and more particularly and distinctly claim what Applicant regards as his invention. No new matter has been introduced by these amendments.

In view of the preceding amendments and remarks, it is submitted that pending claims 12-29 are in condition for allowance and a prompt Notice of Allowance is earnestly solicited.

It is believed that there are no additional fees due in connection with the filing of this response. However, if any such fees are due, including any fee for extension of time, the Commissioner is hereby authorized to charge such fees to our Deposit Account No. 06-916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:



Allen Jensen
Reg. No. 28,224

Dated: July 15, 1998

by

Reg. No. 32,220

09101572 24910150

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000